











Active substances set

Search phrase: Liver cancer


Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Liver cancer

Regorafenib	Regorafenib is indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.	 NO REIMBURSEMENT  ESMO
Cabozantinib	Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	 NO REIMBURSEMENT  ESMO
Ramucirumab	Ramucirumab monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.	 NO REIMBURSEMENT  ESMO
Ipilimumab	Hepatocellular carcinoma (HCC) Ipilimumab in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.	 NO REIMBURSEMENT  ESMO
Nivolumab	Hepatocellular carcinoma (HCC) Nivolumab in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.	 NO REIMBURSEMENT  ESMO

Lenvatinib

Lenvatinib as monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

- 

REIMBURSEMENT
WITH RESTRICTIONS
- 

ESMO

Atezolizumab

Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.


- 


REIMBURSEMENT
WITH RESTRICTIONS
- 

ESMO

Durvalumab

Hepatocellular Carcinoma (HCC) Durvalumab as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Durvalumab in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).


- 


REIMBURSEMENT
WITH RESTRICTIONS
- 

ESMO

Tremelimumab

Tremelimumab in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

- 

FULL
REIMBURSEMENT
- 

ESMO